Clinical Trial Immunotherapy for Lung Cancer Treatment

2024 Symposium | Tools for Treatment: Chemotherapy, Immunotherapy, & Combination TherapiesПодробнее

TIM-3 Targeting T Cell Exhaustion for Better Immunotherapy OutcomesПодробнее

Precision Cancer Medicine and Immunotherapy | Duke Cancer InstituteПодробнее

TiNiVO-2 Study ESMO 2024 - Re-challenging Patients with ImmunotherapyПодробнее

SCAN FYI Oct 2, 2024: Immunotherapy -- Once of the Latest Treatments for CancerПодробнее

Revolutionizing Cancer Treatment: Breakthroughs in Precision Medicine and ImmunotherapyПодробнее

New Strategies to Overcome Immunotherapy Resistance in NSCLCПодробнее

Dr. Nasser Altorki: Neoadjuvant immunotherapy and radiation boosts response in NSCLCПодробнее

Leveraging Immunotherapy and EGFR Targeted Treatment in Unresectable Stage III NSCLCПодробнее

Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy AnniversaryПодробнее

CRSF | Dr. Madala Ravikrishna: Neoadjuvant & Adjuvant Immunotherapy in Early Stage Lung CancerПодробнее

Restorative microbiota therapy with chemo-immunotherapy in NSCLCПодробнее

The role of gut microbiome on immunotherapy outcomes in lung cancerПодробнее

Impact of prior immunotherapy on hepatotoxicity with KRAS G12C inhibitorsПодробнее

2022 04 29 IMMUNOTHERAPY AND COLORECTAL CANCERПодробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

CRSF 7th Masterclass | Dr. Anup Toshniwal: Immunotherapy for Patients with Poor Performance StatusПодробнее

AK112 (Ivonescimab Injection) is an innovative PD-1/VEGF bispecific tumor immunotherapy medication.Подробнее

Update from ESMO 2024: Immunotherapy (IO) for HCCПодробнее

The future of chemo-immunotherapy in resectable non-small cell lung cancerПодробнее